Stock STOK STOKE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Stoke Therapeutics, Inc.

Equities

STOK

US86150R1077

Market Closed - Nasdaq
Other stock markets
 21:00:00 07/05/2024 BST 		5-day change 1st Jan Change
11.94 USD +0.59% Intraday chart for Stoke Therapeutics, Inc. +8.25% +127.00%
05-07 Canaccord Genuity Adjusts Price Target on Stoke Therapeutics to $20 From $21, Maintains Buy Rating MT
05-06 Earnings Flash (STOK) STOKE THERAPEUTICS Reports Q1 Revenue $4.2M MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Stoke Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Stoke Therapeutics Appoints Thomas Leggett CFO
Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer
Sector Update: Health Care Stocks Advance Premarket Thursday
Stoke Therapeutics Plans $75 Million Public Offering
MÄRKTE USA/Etwas leichter - Zurückhaltung vor Inflationsdaten
Sector Update: Health Care Stocks Advance Late Afternoon
Stoke Therapeutics Rises After Investigational Drug Shows Improvement in Dravet Syndrome Patients
Top Midday Gainers
MÄRKTE USA/Gut behauptet - Hoffen auf Inflationsdaten
Wall Street Set to Open Modestly Higher Tuesday Ahead Consumer Confidence Reading
US Futures Trend Higher Ahead of Durable Goods, House Prices, Consumer Confidence Readings
Top Premarket Gainers
MÄRKTE USA/Etwas fester - Hoffen auf Preisdaten
Stoke Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Stoke Therapeutics, Inc Announces New Data that Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome
Stoke Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Stoke Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Stoke Therapeutics, Inc. Appoints Ian Smith to Board of Directors
Stoke Therapeutics, Inc. Presents Data Related to the Ongoing Clinical Development of Stk-001 for the Treatment of Dravet Syndrome
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. STOK Stock
  4. News Stoke Therapeutics, Inc.
  5. Other languages